Omeros (OMER) Other Non-Current Liabilities (2021 - 2026)
Omeros (OMER) posted Other Non-Current Liabilities of $84.0 million for Q1 2026, down 46.54% sequentially from $157.2 million in Q4 2025, and up 1766.81% YoY from $4.5 million in Q1 2025.
Analysis
Omeros (OMER) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Omeros has reported Other Non-Current Liabilities for 6 years, with the latest figure at $84.0 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 1766.81% year-over-year to $84.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.0 million (up 1766.81% YoY) and the FY2025 annual result came in at $157.2 million, up 3391.91% from the prior year.
- Other Non-Current Liabilities retreated to $84.0 million in Q1 2026 per OMER's latest filing, from $157.2 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $157.2 million in Q4 2025 and troughed at $444000.0 in Q4 2022.
- A 5-year average of $17.1 million and a median of $2.1 million in 2023 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities plunged 60.18% in 2022, then surged 3391.91% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $444000.0 in 2022, then surged by 370.27% to $2.1 million in 2023, then surged by 115.57% to $4.5 million in 2024, then soared by 3391.91% to $157.2 million in 2025, then sank by 46.54% to $84.0 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $84.0 million, $157.2 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 55.22 Mn |
| Mar 31, 2026 | 84.03 Mn |
| Dec 31, 2025 | 157.17 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 4.50 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 4.50 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Jun 30, 2023 | 496,000.00 |
| Mar 31, 2023 | 452,000.00 |
| Dec 31, 2022 | 444,000.00 |
| Sep 30, 2022 | 999,000.00 |
| Jun 30, 2022 | 961,000.00 |
| Mar 31, 2022 | 922,000.00 |
| Dec 31, 2021 | 1.12 Mn |